Literature DB >> 26880508

Overactive Bladder.

Nicola White1, Cheryl B Iglesia2.   

Abstract

Overactive bladder (OAB) is a condition affecting millions of individuals in the United States. Anticholinergics are the mainstay of treatment. Bladder botulinum toxin injections have shown an improvement in symptoms of OAB equivalent to anticholinergic therapy. Percutaneous tibial nerve stimulation can decrease symptoms of urinary frequency and urge incontinence. Sacral neuromodulation for refractory patients has been approved by the Food and Drug Administration for treatment of OAB, urge incontinence, and urinary retention. Few randomized, head-to-head comparisons of the different available alternatives exist; however, patients now have increasing options to manage their symptoms and improve their quality of life.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticholinergics; Bladder botulinum toxin (Botox) injection; Overactive bladder; Sacral neuromodulation; Urinary incontinence

Mesh:

Substances:

Year:  2016        PMID: 26880508     DOI: 10.1016/j.ogc.2015.10.002

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  9 in total

1.  Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.

Authors:  Yaoguang Zhang; Peng Zhang; Xiaojun Tian; Guoqing Chen; Yan Li; Yong Zhang; Zhihui Xu; Zhongqing Wei; Wei Zhang; Lulin Ma; Benkang Shi; Limin Liao; Jianye Wang
Journal:  World J Urol       Date:  2019-02-26       Impact factor: 4.226

2.  [Outcome of surgical management and pathogenesis of female primary bladder neck obstruction].

Authors:  X P Zhang; W Y Zhang; F Huo; H Hu; Q Wang; K X Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-18

Review 3.  PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency.

Authors:  Ruida Hou; Ying Yu; Jianxiong Jiang
Journal:  Biochem Pharmacol       Date:  2020-12-09       Impact factor: 5.858

4.  Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.

Authors:  D Sussman; A Yehoshua; J Kowalski; W Lee; J Kish; S Chaudhari; B Murray
Journal:  Int J Clin Pract       Date:  2017-03       Impact factor: 2.503

5.  Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder.

Authors:  Qin-Qin Gong; Yu-Qiong Xu; Jun Xu; Xiao-Yan Ding; Chong Guo
Journal:  Front Pharmacol       Date:  2020-01-15       Impact factor: 5.810

6.  The efficacy and safety of antimuscarinics for the prevention or treatment of catheter-related bladder discomfort: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Zhongbao Zhou; Yuanshan Cui; Xiaoyi Zhang; Youyi Lu; Zhipeng Chen; Yong Zhang
Journal:  Perioper Med (Lond)       Date:  2021-12-14

7.  Daidzein is the in vivo active compound of Puerariae Lobatae Radix water extract for muscarinic receptor-3 inhibition against overactive bladder.

Authors:  Yining Qiang; Lu Bai; Shuran Tian; Yi Ma; Pingxiang Xu; Mingchang Cheng; Yi Wu; Xiaorong Li; Ming Xue; Xuelin Zhou
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

8.  The Relationship Between Urinary Incontinence, Mobility Limitations, and Disability in Older Women.

Authors:  Tatiana V Sanses; Bela Kudish; Jack M Guralnik
Journal:  Curr Geriatr Rep       Date:  2017-05-05

Review 9.  Neuromodulation of the Posterior Tibial Nerve for the Control of Urinary Incontinence.

Authors:  Álvaro Astasio-Picado; María García-Cano
Journal:  Medicina (Kaunas)       Date:  2022-03-17       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.